Abstract
Lower-grade gliomas (LGGs), which are uniformly fatal in young adults, are classified as grades II-III tumors according to their histological features. The NFκB transcription factor, a crucial player in cancer initiation and progression, is inactivated in the cytoplasm by inhibitory proteins (IκBs) that have been shown to exert tumor-suppressor activity. Therefore, using The Cancer Genome Atlas copy number alteration and RNA-Seq data from 398 patients, we evaluated the association between the expression and dosage of NFKBIA, which encodes IκBα, and the overall malignancy of LGGs. Deletion and low expression of NFKBIA were associated with enhanced tumor aggressiveness and poor prognosis in LGGs. Accordingly, the dosage and expression of NFKBIA were independent prognostic factors for 5-year survival (dosage: P = 0.016; expression: P = 0.002) and 5-year recurrence-free survival (dosage: P = 0.009; expression: P = 0.005). Moreover, gene set enrichment analyses and co-expression network analyses indicated a role for NFKBIA in the negative regulation of cell proliferation, possibly through the modulation of downstream NFκB activation. Overall, the present findings reveal the prognostic value of NFKBIA in LGGs, reinforcing the relevance of NFκB signaling in the development and progression of gliomas.
Similar content being viewed by others
Introduction
Lower-grade gliomas (LGGs), which are uniformly fatal in young adults, are infiltrative brain tumors that include astrocytomas, oligoastrocytomas and oligodendrogliomas1. The World Health Organization (WHO) classifies these tumors as grades II-III, primarily based on histological features such as mitotic activity, cellularity, nuclear atypia, microvascular proliferation, and necrosis2. In addition to traditional morphological histopathology, detailed molecular classification of gliomas also contributes to the WHO grading schemes and will be incorporated into a new integrated diagnosis scheme3,4,5. In this sense, molecular pathology will contribute to the stratification of patients in treatment-specific subgroups, which will lead to the development of more personalized and biologically grounded therapies6,7.
The NFκB family of transcription factors has an essential role in many biological processes, such as inflammation, innate immunity, cell proliferation and apoptosis8. Additionally, aberrant activation of NFκB is increasingly recognized as a crucial factor in cancer initiation and progression9. All five members of this protein family (p65, p100/p50, p102/p52, c-Rel and RelB) share a Rel homology domain (RHD), which mediates their dimerization and DNA binding10. In most quiescent cells, NFκB dimers remain inactive in the cytoplasm, due to their interaction with inhibitory proteins of the IκB family. The IκBs are characterized by ankyrin repeats, which interact with the RHDs of NFκB proteins, thereby making them transcriptionally inactive11. The canonical NFκB pathway is typically triggered by pro-inflammatory cytokines and genotoxic stress, leading to the phosphorylation of IκBα and release of NFκB dimers, mainly p50:p65. NFκB can then translocate to the nucleus and activate the expression of target genes involved in the control of inflammation, cell proliferation, apoptosis, migration and angiogenesis12.
NFκB activity in gliomas is significantly higher than in normal brain tissues and phospho-IκBα protein levels have been shown to negatively correlate with tumor grade13,14,15. Additionally, recent studies have revealed that NFKBIA, which encodes IκBα, is deleted in approximately 25% of grade IV gliomas (glioblastomas), the most aggressive primary brain tumors16. Interestingly, after restoring NFKBIA expression in cells cultured from tumors harboring an NFKBIA deletion, the malignant phenotype was attenuated and an increase in chemotherapy sensitivity was observed. More importantly, patients with tumors harboring a deletion or low expression of NFKBIA demonstrated decreased survival16. Accordingly, treatment with nanoparticles loaded with recombinant IκBα and curcumin, a natural polyphenol that inhibits the phosphorylation of IκBα, has been shown to decrease the expression of NFκB target genes such as CCND1, CCNE1, BCL2L1 and COX2, thereby inducing apoptotic cell death in a glioblastoma cell line17.
Given the potential role of NFKBIA in glioblastoma development and progression15,16,17, we aimed to investigate, in LGGs, the impact of NFKBIA dosage and expression on patient survival, overall malignancy and the downstream activation of NFκB.
Results
NFKBIA deletion frequency and mRNA expression
NFKBIA deletion was observed in approximately 7% of LGGs from The Cancer Genome Atlas (TCGA) cohort. The deletion was more common in grade III than in grade II gliomas (Fig. 1, Table 1), regardless of histologic subtype (Fig. 1). Interestingly, grade III astrocytomas, the most aggressive type of LGG, showed the highest frequency of NFKBIA deletion (16.84%, Fig. 1a). Deletions were associated with reduced NFKBIA mRNA expression (Fig. 2). Accordingly, grade III gliomas expressed significantly lower levels of NFKBIA mRNA compared to grade II gliomas. (Fig. 2, Table 2). Patients with LGGs harboring a deletion of NFKBIA were significantly older than those with a normal dosage (Table 1).
Impact of NFKBIA dosage and mRNA expression on patient survival
When we performed univariate analyses of patient survival using Kaplan-Meier curves and Cox univariate regression models, we found that the dosage and expression of NFKBIA were significant prognostic factors in LGGs (Fig. 3 and Table 3). Both deletion and low expression of NFKBIA were associated with poor 5-year survival (dosage: HR = 6.54, P < 0.001; expression: HR = 0.47, P < 0.001, Table 3) and 5-year recurrence-free survival (RFS; dosage: HR = 3.65, P = 0.001; expression: HR = 0.58, P = 0.001; Table 3). To control for possible confounding factors, we also used a multivariate approach, the Cox multivariate regression model, which allowed us to evaluate survival considering multiple variables simultaneously. After adjusting for age, gender, histological subtype and tumor grade, the dosage and expression of NFKBIA remained significant prognostic factors for both 5-year survival (dosage: HR = 2.15, P = 0.016; expression: HR = 0.54, P = 0.002; Tables 4 and 5) and 5-year RFS (dosage: HR = 3.11 P = 0.009; expression: HR = 0.61, P = 0.005; Tables 4 and 5). Notably, in the 5-year RFS analyses no other variable was independently associated with prognosis (Tables 4 and 5).
Effects of NFKBIA dosage and mRNA expression on KEGG biological pathways
To evaluate the biological relevance of NFKBIA dosage and expression in LGGs, we performed gene set enrichment analysis (GSEA) using genes ranked according to i) their differential expression in tumors with NFKBIA deletion or ii) their Pearson’s correlation with the expression of NFKBIA. Among KEGG pathways overexpressed in tumors harboring a deletion of NFKBIA, 32 were significantly enriched (P < 0.05 corrected by false discovery rate, FDR; Supplementary Table S1). On the other hand, among KEGG pathways negatively correlated with the expression of NFKBIA, 10 were significantly enriched (P < 0.05 corrected by FDR; Supplementary Table S2). Interestingly, all three pathways significantly enriched in both analyses, namely “cell cycle,” “DNA replication” and “mismatch repair,” are implicated in the process of cell proliferation (Fig. 4).
Co-expression analysis of NFκB target genes
Given that IκBα proteins inhibit the transcriptional activity of p50:p65 NFκB dimers, we sought to investigate if the anti-proliferative role of NFKBIA, indicated by the GSEA, was associated with changes in the expression pattern of NFκB target genes. As such, we performed co-expression network analyses using NFκB target genes involved in the positive control of cell proliferation, such as CCND1, MYC, IL6 and EGFR. Interestingly, both deletion and low expression of NFKBIA significantly affected the network’s spectral distribution (dosage: P = 0.036; expression: P = 0.004; Fig. 5), showing that pro-proliferation NFκB target genes were differentially co-expressed between phenotypes (deleted vs. normal and high vs. low; Fig. 5).
Discussion
Previous studies have suggested a correlation between the levels of phospho-IκBα and the grade of gliomas15; however, to the best of our knowledge, there is no available data assessing the biological and clinical implications of NFKBIA dosage and expression in LGGs. Thus, the present findings demonstrate that deletion and low expression of NFKBIA are associated with enhanced tumor aggressiveness and poor prognosis in LGGs. Moreover, our data indicate a role for NFKBIA in the negative control of cell proliferation, possibly through inhibition of NFκB transcriptional activity.
The NFκB signal transduction cascade is a multi-component pathway that ultimately controls the expression of genes involved in multiple biological processes11. The effect of upstream components of the pathway on the activity of NFκB usually determines the expression pattern of target genes18,19. The dysregulation of the NFκB pathway at different levels, either by mutations, epigenetic mechanisms or pharmacological means, is involved in many human diseases, especially chronic inflammation, immunodeficiency and cancer20,21,22,23. Notably, NFκB is aberrantly activated in tumor cells; however, the mechanisms of activation appear to be complex and vary in different tumor types9,12. Given that the modulation of NFκB activity has an important role in the prevention and management of cancer, careful evaluation of its complex regulation in different tumors is essential24,25.
In this study, we demonstrate that NFKBIA, which encodes IκBα, a critical negative regulator of NFκB canonical activation, is heterozygously deleted in approximately 7% of LGGs. Additionally, grade III tumors presented a higher frequency of NFKBIA deletion, combined with reduced mRNA expression, suggesting an association between NFKBIA and overall glioma malignancy. More importantly, the dosage and expression of NFKBIA were revealed as grade- and histological subtype-independent prognostic factors for both 5-year survival and 5-year RFS. In both cases, the deletion and low expression of NFKBIA were associated with poor prognosis, corroborating the idea that IκB proteins demonstrate tumor suppressor functions23,26.
When released from IκBα proteins, p50:p65 NFκB dimers can promote cell proliferation by regulating the mRNA expression of cell cycle machinery genes, inflammatory cytokines and growth factors27,28,29,30. Accordingly, our data indicate that NFKBIA has a role in the negative control of cell proliferation, changing the co-expression pattern of NFκB target genes. In this sense, GSEA revealed that the expression of many genes involved in cell cycle progression was increased in tumors with NFKBIA deletion and negatively correlated with the expression of NFKBIA. Moreover, co-expression network analyses suggested that deletions and low expression of NFKBIA could promote cell proliferation possibly by interfering with the expression pattern of NFκB target genes. Nevertheless, further studies are needed to better understand the mechanistic implications of deletions and low expression of NFKBIA in the control of NFκB signaling in LGGs. In particular, it would be relevant to determine which NFκB dimers are more frequently activated in the absence of NFKBIA, and if this aberrant activation could contribute to the transcription of pro-tumoral genes and, consequently, to the acquisition of a more malignant phenotype in vitro and in vivo.
The characterization of molecular markers/profiles of LGGs associated with poor outcomes can lay the biological groundwork for the development of rationally designed targeted therapies to improve patient survival. In this sense, despite the limitations intrinsic to our data, the present findings support a role for NFKBIA in the control of LGG malignancy, reinforcing the relevance of NFκB signaling in the development and progression of gliomas31. Thus, therapies that stabilize NFκB-IκBα interactions in the cytoplasm might effectively restrain oncogenic signaling, especially in tumors presenting a deletion or low expression of NFKBIA.
Materials and Methods
TCGA data
We obtained clinical, RNA-Seq (V2), and Copy Number Alteration (CNA) level 3 data from LGGs in TCGA32 using the Cancer Genomics Hub portal33 and the TCGA-Assembler package34. Datasets comprised clinical data from 530 patients, CNA data from 512 patients and RNA-Seq data from 528 patients, the intersection of which consisted of 512 cases for which all three types of data were present. Patients with missing histological grade were excluded from this study, leading to a set of 398 cases, which were used in all the analyses. All data pre-processing was performed using the R software package (http://www.r-project.org).
CNA detection was performed using the Affymetrix (Santa Clara, USA) Genome-Wide Human SNP Array 6.0 platform, with approximately 1.8 million genetic markers divided into 900,00 SNP and 906,600 CNA detection probes, spread across the human genome. Data processing was performed using GenePattern’s Affymetrix SNP6 Copy Number Inference pipeline. Normalization of CNA values was performed using the circular binary segmentation algorithm35. The magnitude of NFKBIA CNAs was measured using a simplified version of a previous classification scheme, where tumors were labeled as “complete deletion” when the log2 of the normalized CNA value was less than or equal to −1: “deletion,” when the value was between −1 and −0.2, or “normal,” when the value was between −0.2 and 0.236.
RNA sequencing was performed using the Illumina HiSeq 2000 platform and data processing was performed through the second analysis pipeline (RNASeqV2), using MapSplice37 and RSEM38 for gene mapping and gene expression quantification, respectively. Tumors were dichotomized, as “low” or “high,” according to NFKBIA expression using the median expression value as a cutoff.
GSEA
All genes from TCGA RNAseq dataset were pre-ranked according to: i) their differential expression (fold change) comparing tumors with normal and deleted NFKBIA dosages (mediandeleted/mediannormal), or ii) Pearson’s correlation between their expression and the expression of NFKBIA. GSEA was performed using GSEA v4.039 and KEGG pathways40. Enrichment scores (ES) were calculated based on a Kolmogorov–Smirnov statistic and tested for significance using 1,000 permutations. ES were further normalized (NES) to account for the size of each gene set. P-values corresponding to each NES were corrected for multiple comparisons by the FDR procedure39. Adjusted P-values < 0.05 were considered statistically significant.
Co-expression network analysis
To construct co-expression networks, we selected NFκB target genes involved in the positive control of cell proliferation, namely: CCND1, CCND2, CCND3, CCNE1, CDK2, MYC, TNF, IL1B, IL6, EGFR, MDK, PTGS2. In these undirected weighted co-expression networks, genes are nodes, while edges represent the pairwise correlations between gene expressions. Edge weights correspond to the Spearman’s correlation coefficient between gene pairs. Networks were visualized using the igraph package41 in R (http://www.r-project.org).
We used CoGA software42 to compare networks built according to NFKBIA dosage (normal vs. deleted) and expression (high vs. low). CoGA identifies structural differences between networks by using graph spectral distribution. The spectrum of a graph is the set of eigenvalues of its adjacency matrix. The spectrum is a general way to describe the structure of a network and can be used to determine if two networks were generated by the same model43. We considered that two networks were significantly different by rejecting the null hypothesis of the equality test with an adjusted P-value (corrected for multiple comparisons by the FDR procedure) threshold of 5%.
Statistical Analysis
Two-group comparisons were analyzed using two-sided Student’s t tests. The chi-square test was used to access the association between various categorical clinicopathological characteristics and NFKBIA dosage (normal vs. deleted) and expression (high vs. low). We evaluated the impact of NFKBIA dosage and expression on both patient overall survival and RFS using Kaplan-Meier curves and the log-rank test44 in addition to uni- and multivariate Cox proportional hazard models45. HRs, including 95% confidence intervals, were calculated. The survival time was right-censored by 5 years. Statistical analyses were performed with GraphPad Prism 6 and R (http://www.r-project.org). P-values < 0.05 were considered statistically significant.
Additional Information
How to cite this article: Kinker, G. S. et al. Deletion and low expression of NFKBIA are associated with poor prognosis in lower-grade glioma patients. Sci. Rep. 6, 24160; doi: 10.1038/srep24160 (2016).
References
Ricard, D. et al. Primary brain tumours in adults. Lancet 379, 1984–1996 (2012).
Louis, D. N. et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114, 97–109 (2007).
Louis, D. N. et al. International Society Of Neuropathology—Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol. 24, 429–435 (2014).
Eckel-Passow, J. E. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N. Engl. J. Med. 372, 2499–2508 (2015).
Weller, M. et al. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome-and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol. 129, 679–693 (2015).
Vitucci, M., Hayes, D. N. & Miller, C. R. Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy. Br. J. Cancer 104, 545–553 (2011).
Weller, M. et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat. Rev. Neurol. 6, 39–51 (2010).
Hayden, M. S. & Ghosh, S. S. NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 26, 203–234 (2012).
Karin, M., Cao, Y., Greten, F. R. & Li, Z. M. NF-κB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2, 301–310 (2002).
Ghosh, S., May, M. J. & Kopp, E. B. NF-kappa B. and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. of Immunol. 16, 225–60 (1998).
Gilmore, T. D. Introduction to NF-κB: players, pathways, perspectives. Oncogene 25, 6680–6684 (2006).
Hoesel, B. & Schmid, J. A. The complexity of NF-κB signaling in inflammation and cancer. Mol. Cancer 12, 1–15 (2013).
Angileri, F. F. et al. Nuclear factor‐κB activation and differential expression of survivin and Bcl‐2 in human grade 2–4 astrocytomas. Cancer 112, 2258–2266 (2008).
Wang, H., Zhang, W., Huang, H. J., Liao, W. S. & Fuller, G. N. Analysis of the activation status of Akt, NF- κB, and Stat3 in human diffuse gliomas. Lab. Invest. 84, 941–951 (2004).
Korkolopoulou, P. et al. Expression of nuclear factor-κB in human astrocytomas: relation to pIκBa, vascular endothelial growth factor, Cox-2, microvascular characteristics, and survival. Hum. Pathol. 39, 1143–1152 (2008).
Bredel, M. et al., NFKBIA deletion in glioblastomas. N. Engl. J. Med. 364, 627–637 (2011).
Banerjee, S., Sahoo, A. K., Chattopadhyay, A. & Ghosh, S. S. Recombinant IκBα-loaded curcumin nanoparticles for improved cancer therapeutics. Nanotechnology 25, 345102 (2014).
Courtois, G. & Gilmore, T. D. Mutations in the NF-κB signaling pathway: implications for human disease. Oncogene 25, 6831–6843 (2006).
Lin, Y., Bai, L., Chen, W. & Xu, S. The NF-κB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin. Ther. Targets 14, 45–55 (2010).
Smahi, A. et al. Genomic rearrangement in NEMO impairs NF-κB activation and is a cause of incontinentia pigmentim. Nature 405, 466–472 (2000).
Courtois, G. et al. A hypermorphic IκBα mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency. J. Clin. Invest. 112, 1108 (2003).
Barth, T. F. et al. Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma. Blood 101, 3681–3686 (2003).
Cabannes, E., Khan, G., Aillet, F., Jarrett, R. F. & Hay, R. T. Mutations in the IkBa gene in Hodgkin’s disease suggest a tumour suppressor role for IkBa. Oncogene 18, 3063–3070 (1999).
Atkinson, G. P., Nozell, S. E. & Benveniste, E. T. N. NF-κB and STAT3 signaling in glioma: targets for future therapies. Expert Rev. Neurother. 10, 575–86 (2010).
Baud, V. & Karin, M. Is NF-κB a good target for cancer therapy ? Hopes and pitfalls. Nat. Rev. Drug Discov. 8, 33–40 (2009).
Jungnickel, B. et al. Clonal deleterious mutations in the IκBα gene in the malignant cells in Hodgkin’s lymphoma. J. Exp. Med. 191, 395–402 (2000).
Hinz, M. et al. NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol. Cell. Biol. 19, 2690–2698 (1999).
Hsia, C. Y., Cheng, S., Owyang, A. M., Dowdy, S. F. & Liou, H. C. c-Rel regulation of the cell cycle in primary mouse B lymphocytes. Int. Immunol. 14, 905–916 (2002).
McFarland, B. C. et al. NF-kappaB-induced IL-6 ensures STAT3 activation and tumor aggressiveness in glioblastoma. PLoS One 8, e78728 (2013).
Bonavia, R. et al. EGFRvIII promotes glioma angiogenesis and growth through the NF-kappaB, interleukin-8 pathway. Oncogene 31, 4054–66 (2012).
Puliyappadamba, V. T., Hatanpaa, K. J., Chakraborty, S. & Habib, A. A. The role of NF-κB in the pathogenesis of glioma. Mol. Cell. Oncol 1, e963478 (2014).
Tomczak, K., Czerwińska, P. & Wiznerowicz, M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp. Oncol. 19, A68–77 (2015).
Wilks, C. et al. The Cancer Genomics Hub (CGHub): overcoming cancer through the power of torrential data. Database 2014, bau093 (2014).
Zhu, Y., Qiu, P. & Ji, Y. TCGA-Assembler: open-source software for retrieving and processing TCGA data. Nat. Methods 11, 599–600 (2014).
Olshen, A. B., Venkatraman, E. S., Lucito, R. & Wigler, M. Circular binary segmentation for the analysis of array based DNA copy number data. Biostatistics 5, 557–572 (2004).
Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462–77 (2013).
Wang, K. et al. MapSplice: accurate mapping of RNA-Seq reads for splice junction discovery. Nucleic Acids Res. 38, e178–e178 (2010).
Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011).
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545–15550 (2005).
Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H. & Kanehisa, M. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 27, 29–34 (1999).
Csardi, G. & Nepusz, T. The igraph software package for complex network research. InterJournal, Complex Systems 1695, 1–9 (2006).
de Siqueira Santos, S. et al. CoGA: An R Package to Identify Differentially Co-Expressed Gene Sets by Analyzing the Graph Spectra. PLoS One 10, e0135831 (2015).
Takahashi, D. Y., Sato, J. R., Ferreira, C. E. & Fujita, A. Discriminating different classes of biological networks by analyzing the graphs spectra distribution. PLoS One 7, e49949 (2012).
Clark, T. G., Bradburn, M. J., Love, S. B. & Altman, D. G. Survival analysis part I: basic concepts and first analyses. Br. J. Cancer 89, 232 (2003).
Bradburn, M. J., Clark, T. J., Love, S. B. & Altman, D. G. Survival analysis part II: multivariate data analysis–an introduction to concepts and methods. Br. J. Cancer 89, 431 (2003).
Acknowledgements
G.S.K was supported by fellowships from CNPq (162670/2014-1) and the São Paulo Research Foundation (FAPESP, 2014/27287-0), A.M.T was supported by a fellowship from FAPESP (2015/01507-7) and V.J.C was supported by a fellowship from the Coordination for the Improvement of Higher Education Personnel (CAPES, Brazilian Ministry of Education). A.F. received financial support from FAPESP (2013/03447-6, 2014/09576-5, and 2015/01587-0), the Brazilian National Council for Research in Science and Technology (CNPq, 304020/2013-3 and 473063/2013-1) and the eScience Research Network (Research Support Center, University of São Paulo).
Author information
Authors and Affiliations
Contributions
G.S.K., A.M.T., V.J.C. and F.P.L. designed the study and performed the analyses. All authors analyzed the data and wrote the manuscript. A.F. critically revised the manuscript for important intellectual content and has given the final approval of the version to be published.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Rights and permissions
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
About this article
Cite this article
Kinker, G., Thomas, A., Carvalho, V. et al. Deletion and low expression of NFKBIA are associated with poor prognosis in lower-grade glioma patients. Sci Rep 6, 24160 (2016). https://doi.org/10.1038/srep24160
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/srep24160
- Springer Nature Limited
This article is cited by
-
Identification of Systems Level Molecular Signatures from Glioblastoma Multiforme Derived Extracellular Vesicles
Journal of Molecular Neuroscience (2021)